CJC-1295 and Immune Function Research: GH Axis, Thymic Biology and Immunosenescence UK 2026

This article is for Research Use Only. CJC-1295 is a research peptide not approved for human therapeutic use in the UK. All information is provided for scientific and educational purposes only.

Introduction: The GH Axis and Immune System Regulation

The somatotropic axis — encompassing growth hormone (GH), growth hormone-releasing hormone (GHRH), and insulin-like growth factor-1 (IGF-1) — is intimately intertwined with immune system development, maintenance, and function. GH receptors (GHR) and IGF-1 receptors (IGF-1R) are expressed on the full spectrum of immune cells: T lymphocytes, B lymphocytes, natural killer (NK) cells, monocytes, macrophages, and dendritic cells. Furthermore, the thymus — the primary organ of T cell maturation — is a direct target of GH and IGF-1 signalling throughout life.

CJC-1295 is a synthetic GHRH analogue incorporating Drug Affinity Complex (DAC) technology (CJC-1295 with DAC) or presented without DAC as CJC-1295 (also termed Mod GRF 1-29). In research contexts, these peptides stimulate pituitary GH secretion and consequent IGF-1 production. Their potential role in immune research derives from this somatotropic axis activation and its downstream effects on thymic architecture, lymphocyte biology, and age-related immune decline.

Thymic Biology: GH and IGF-1 as Thymopoietic Regulators

The thymus involutes progressively from adolescence, a process of age-related structural and functional decline that reduces thymic output of naïve T cells. By the sixth decade, thymic volume is reduced by approximately 70–80% compared to peak adolescent size, replaced largely by adipose tissue. This thymic involution is a primary driver of immunosenescence — the age-associated decline in immune competence characterised by accumulation of terminally differentiated effector T cells, reduced naïve T cell diversity (TCR repertoire narrowing), and impaired responses to novel antigens and vaccines.

GH and IGF-1 are established regulators of thymic biology at multiple levels. Thymic epithelial cells (TECs), which provide the stromal scaffold for T cell development and selection, express both GHR and IGF-1R. GH/IGF-1 signalling promotes TEC proliferation, survival, and cytokine production (IL-7, SCF, Wnt ligands) that support thymocyte development at each checkpoint: DN (double negative), DP (double positive), and SP (single positive) stages. In GH-deficient animal models, thymic involution is accelerated and thymic output is reduced; conversely, GH or IGF-1 administration partially reverses thymic atrophy and increases recent thymic emigrants (RTEs) in aged animals.

CJC-1295 and Thymic Regeneration Research

The link between CJC-1295 (via pituitary GH stimulation and IGF-1 production) and thymic regeneration represents a growing area of research interest, particularly in the context of immunosenescence and post-chemotherapy immune reconstitution. Preclinical research in aged rodent models has demonstrated that GHRH analogue treatment can increase thymic cellularity, partially restore the cortical-medullary architecture of involuted thymuses, increase intrathymic T cell progenitor populations, and augment peripheral naïve CD4+ and CD8+ T cell numbers.

These findings have mechanistic parallels with research using direct GH or IGF-1 supplementation, but GHRH analogues offer the theoretical advantage of physiologically pulsatile GH release (preserving natural somatostatin feedback), reducing the risk of supraphysiological IGF-1 levels that could promote unwanted cellular proliferation. For immune research models, this physiological modulation profile makes CJC-1295 a useful tool for studying axis-level (rather than pharmacological) GH axis contributions to thymopoiesis.

Lymphocyte Biology and GH/IGF-1 Signalling

Beyond thymic development, GH and IGF-1 modulate peripheral lymphocyte function at multiple levels. Key research-relevant mechanisms include:

T cell proliferation and survival: IGF-1R signalling through PI3K–Akt promotes T cell survival by suppressing pro-apoptotic signals (Bad, Bax, FOXO transcription factors) and enhancing expression of anti-apoptotic proteins (Bcl-2, Bcl-xL). GH can co-stimulate T cell proliferation alongside T cell receptor (TCR) and CD28 signals, amplifying antigen-driven clonal expansion in vitro and in vivo models.

B lymphocyte function: GHR and IGF-1R are expressed on B cells at all developmental stages. IGF-1 promotes B cell survival, proliferation, and immunoglobulin class switching. In GH-deficient states, B cell numbers and antibody responses to T-cell-dependent antigens are reduced. GHRH analogue restoration of the GH axis in research models may therefore modulate humoral immunity — an area of relevance to age-related vaccine hyporesponsiveness research.

NK cell activity: Natural killer cells, critical for innate immune surveillance of virus-infected and tumour cells, express GHR and respond to GH with enhanced cytotoxic activity, interferon-γ (IFN-γ) production, and ADCC (antibody-dependent cellular cytotoxicity) capacity. Age-related GH decline may contribute to the reduction in NK cell function observed in immunosenescence.

Macrophage and dendritic cell biology: Tissue macrophages and monocyte-derived dendritic cells express GHR and IGF-1R, modulating their phagocytic capacity, cytokine secretion profiles (IL-1β, TNF-α, IL-10), and antigen-presenting function. GH promotes macrophage activation toward the M1/pro-inflammatory phenotype in some contexts, while IGF-1 can promote M2/anti-inflammatory skewing — reflecting the complex, context-dependent nature of somatotropic immune modulation.

Immunosenescence and the Research Case for GH Axis Restoration

Immunosenescence encompasses both quantitative (reduced naïve lymphocyte output, inverted CD4:CD8 ratios) and qualitative (reduced proliferative capacity, cytokine dysregulation, exhaustion marker upregulation) immune decline. The convergence of somatopause and immunosenescence — both accelerating from the fourth to fifth decade — has prompted research into whether GH axis restoration can partially reverse age-related immune decline.

Landmark work by Fahy et al. (2019) demonstrated that a multi-agent regimen including recombinant GH (alongside metformin and DHEA) produced measurable thymic regeneration in older men, assessed by MRI and epigenetic age clock analysis. While this was direct GH rather than GHRH analogue administration, it establishes biological proof-of-concept that the GH–thymus axis remains amenable to manipulation in aged humans. GHRH analogues like CJC-1295 — operating through physiological pituitary stimulation rather than exogenous GH — offer a research framework for studying whether upstream axis modulation produces comparable thymopoietic effects with a potentially more tolerable safety profile.

Post-Chemotherapy Immune Reconstitution Research

Chemotherapy-induced lymphodepletion is a significant clinical challenge in oncology, producing prolonged immune compromise with associated infection risk, impaired tumour surveillance, and reduced vaccine responsiveness. Thymic reconstitution is the rate-limiting step for recovery of naïve T cell diversity post-chemotherapy or haematopoietic stem cell transplantation (HSCT). Research models utilising GH and IGF-1 to accelerate post-chemotherapy thymic reconstitution have demonstrated reduction in the period of immune vulnerability, with implications for post-HSCT infection outcomes.

CJC-1295, as a GHRH analogue that physiologically elevates GH and IGF-1, represents a research candidate for studying whether somatotropic axis support during the immune reconstitution period accelerates thymic output recovery. Relevant preclinical endpoints include: thymic volume by MRI or micro-CT; RTE frequency (measured by signal joint T cell receptor excision circles, sjTRECs); peripheral naïve T cell (CD45RA+CCR7+) reconstitution; TCR repertoire diversity by high-throughput sequencing; and antigen-specific immune reconstitution following model vaccination.

HIV and Immune Deficiency Research Context

HIV infection produces profound CD4+ T cell depletion through direct cytopathic effects on CD4+ cells and indirect thymic damage. Even with antiretroviral therapy (ART) producing viral suppression, many people with HIV demonstrate incomplete CD4+ T cell recovery — a phenomenon associated with persistent low-level inflammation, thymic dysfunction, and residual immune activation. The overlap between HIV immune deficiency and GH axis abnormalities is well-characterised: untreated HIV is associated with GH deficiency and elevated GH resistance, with reduced IGF-1 levels.

In this research context, GHRH analogues including sermorelin and tesamorelin have been studied more extensively than CJC-1295 (with tesamorelin approved for HIV-associated lipodystrophy). However, CJC-1295’s DAC technology — extending half-life and providing more sustained GH axis stimulation — may offer research advantages for studying chronic immune deficiency contexts where sustained somatotropic support could be beneficial. Research in SIV (simian immunodeficiency virus) models and in vitro human lymphocyte systems provides a foundation for evaluating CJC-1295’s potential in HIV immune biology research.

Cytokine Modulation and Inflammatory Biology

The relationship between GH axis activation and systemic inflammatory cytokine profiles is complex and bidirectional. Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) suppress somatotropic axis function at multiple levels — inhibiting GHRH release, reducing pituitary GH secretion, promoting GH resistance peripherally, and suppressing IGF-1 production. Conversely, GH/IGF-1 can modulate cytokine networks: GH can promote IL-2 and IFN-γ production by T cells (pro-inflammatory), while IGF-1 tends toward anti-inflammatory effects including IL-10 upregulation and TNF-α suppression in some cell contexts.

In research models of chronic low-grade inflammation (characteristic of ageing, metabolic syndrome, and several immune-mediated diseases), GH axis restoration through GHRH analogues may shift the inflammatory cytokine balance. CJC-1295, by producing sustained GH pulsatility and IGF-1 elevation, provides a research tool for dissecting how axis-level GH modulation alters the cytokine environment in aged or metabolically dysregulated systems — relevant to both immunosenescence research and inflammatory disease biology.

Research Design Considerations

Studies examining CJC-1295’s immune effects in preclinical models should account for the baseline somatotropic status of the model organism, as the immunomodulatory effects of GH axis activation are most pronounced in GH-deficient or aged-GH-declining states. In young, eugonadal GH-normal animals, axis stimulation may produce less dramatic immune effects. Aged mouse models (18–24 months C57BL/6) with documented IGF-1 decline provide the most biologically relevant platform for immunosenescence research using GHRH analogues.

Key immune endpoints include: flow cytometric immunophenotyping (naïve, central memory, effector memory, terminally differentiated effector subsets in CD4+ and CD8+ compartments); sjTREC quantification for thymic output; NK cytotoxicity assays (K562 killing, ADCC); B cell subset analysis and antigen-specific antibody titres; cytokine multiplex profiling (Luminex or similar) from stimulated immune cells; and thymic histology (cortical/medullary architecture, Hassall’s corpuscle frequency, cytokeratin-5/8 TEC subtype balance).

Regulatory Framing

CJC-1295 is supplied for research use only under MHRA statutory research exemptions. It is not approved for human therapeutic use, not licensed as a medicine, and not indicated for any immune condition. All research must comply with UK institutional ethics frameworks and applicable Home Office project licences for animal work. No immunological treatment protocols or clinical immune therapy recommendations are derived from this research overview.